keyword
MENU ▼
Read by QxMD icon Read
search

LABA and children

keyword
https://www.readbyqxmd.com/read/27826962/asthma-severity-and-the-controller-prescription-in-children-at-12-tertiary-hospitals
#1
Dong In Suh, Hyeon Jong Yang, Bong Seong Kim, Youn Ho Shin, So Yeon Lee, Geunhwa Park, Woo Kyung Kim, Hyo Bin Kim, Heysung Baek, Ja Kyoung Kim, Jin Tack Kim, Dae Hyun Lim
PURPOSE: Guidelines need to be tailored to where they are applied. We aimed to describe the distinctive asthma severity profile and the pattern of controller prescription in Korean children. METHODS: Twelve pediatric allergists from tertiary medical centers reviewed medical records of all asthmatic children who visited their clinics between September 1 and November 30 of 2013. Controller prescriptions were re-classified into 4 categories, then the prevalence of each asthma severity category and the controller prescription patterns according to asthma severity assessed by a Western (Global Initiative for Asthma, GINA) and an Asia-Pacific (Japanese Pediatric GuideLine, JPGL) guideline were evaluated...
January 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/27735927/inappropriate-asthma-therapy-a-tale-of-two-countries-a-parallel-population-based-cohort-study
#2
Manon Belhassen, Anjan Nibber, Eric Van Ganse, Dermot Ryan, Carole Langlois, Francis Appiagyei, Derek Skinner, Laurent Laforest, Joan B Soriano, David Price
Against recurrent controversies around the safety of short- and long-acting β2-agonists (SABA and LABA), and the National Review of Asthma Deaths inquiry in the United Kingdom, we investigated the prevalence of inappropriate therapy in asthma. Our study aimed to determine the prevalence of inappropriate use of asthma therapy in the United Kingdom and in France. Two interval, parallel, population-based cohorts (2007 and 2013) were developed in each country by using the UK OPCRD and the French EGB databases...
October 13, 2016: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/27677381/prevalence-and-risk-factors-for-asthma-among-children-aged-0-14-years-in-hangzhou-a-cross-sectional-survey
#3
Dan Xu, Yingshuo Wang, Zhimin Chen, Shuxian Li, Yungai Cheng, Li Zhang, Lingzhi Zhao
BACKGROUND: Asthma is a global problem. Prevalence varies among different countries and cities. We aimed to obtain the prevalence, describe the characteristics, and discover factors that may relate to asthma in Hangzhou. METHODS: This cross-sectional study was conducted in Hangzhou. The subjects were children aged 14 years and younger. A control group of non-asthma children that matched in age and sex with each asthmatic patient was also randomly selected and interviewed...
September 27, 2016: Respiratory Research
https://www.readbyqxmd.com/read/27615145/assessing-the-viability-of-long-acting-%C3%AE-2-agonists-in-paediatric-asthma-patients-a-pharmacokinetic-pharmacodynamic-perspective
#4
Maria Gabriella Matera, Barbara Rinaldi, Luigino Calzetta, Mario Cazzola
INTRODUCTION: Long-acting β2-agonists (LABAs) combined with inhaled corticosteroids (ICSs) are still commonly prescribed to asthmatic children. Unfortunately, pediatric LABA use is based primarily on data from adults, despite the fact that children are not simply small adults and the magnitude of changes in dose exposure and/or exposure response may not be solely reflected by differences in body weight. AREAS COVERED: The differences in pharmacokinetics (PK) and pharmacodynamics (PD) of LABAs are described and discussed with reference children and adults...
September 14, 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27612491/tiotropium-in-the-add-on-treatment-of-asthma-in-adults-clinical-trial-evidence-and-experience
#5
Christian Vogelberg
Asthma is a chronic inflammatory airway disease, and its treatment is frequently challenging despite detailed national and international guidelines. While basic anti-inflammatory therapy usually consists of inhaled corticosteroids in doses adapted to the asthma severity, add-on treatment with bronchodilators is essential in more severe asthma. Only recently, the long-acting anticholinergic tiotropium was introduced into the GINA guidelines. This review reports on the studies that have been performed with tiotropium in adult asthmatic patients...
September 9, 2016: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/27582089/vilanterol-and-fluticasone-furoate-for-asthma
#6
Kerry Dwan, Stephen J Milan, Lynne Bax, Nicola Walters, Colin Powell
BACKGROUND: Vilanterol (VI) is a long-acting beta2-agonist (LABA) that binds to the beta2-adrenoceptor on the airway smooth muscle, producing bronchodilation. LABA therapy, which is well established in adults as part of the British Thoracic Society (BTS) Guidelines for the Management of Asthma, leads to improvement in symptoms and lung function and reduction in exacerbations. At present, the commonly used LABAs licensed for use in asthma management (formoterol and salmeterol) require twice-daily administration, whereas VI is a once-daily therapy...
September 1, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27579634/safety-of-adding-salmeterol-to-fluticasone-propionate-in-children-with-asthma
#7
RANDOMIZED CONTROLLED TRIAL
David A Stempel, Stanley J Szefler, Søren Pedersen, Robert S Zeiger, Anne M Yeakey, Laurie A Lee, Andrew H Liu, Herman Mitchell, Kenneth M Kral, Ibrahim H Raphiou, Barbara A Prillaman, Kathleen S Buaron, Suyong Yun Kirby, Steven J Pascoe
BACKGROUND: Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in children. METHODS: We randomly assigned, in a 1:1 ratio, children 4 to 11 years of age who required daily asthma medications and had a history of asthma exacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks...
September 1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27421902/long-acting-%C3%AE-agonist-in-combination-or-separate-inhaler-as-step-up-therapy-for-children-with-uncontrolled-asthma-receiving-inhaled-corticosteroids
#8
Steve Turner, Kathryn Richardson, Clare Murray, Mike Thomas, Elizabeth V Hillyer, Anne Burden, David B Price
BACKGROUND: Adding a long-acting β2-agonist (LABA) to inhaled corticosteroids (ICS) using a fixed-dose combination (FDC) inhaler is the UK guideline recommendation for children aged more than 4 years with uncontrolled asthma. The evidence of benefit of adding an FDC inhaler over a separate LABA inhaler is limited. OBJECTIVE: The objective of this study was to compare the effectiveness of a LABA added as an FDC inhaler, and as a separate inhaler, in children with uncontrolled asthma...
July 12, 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/26774659/childhood-asthma-exacerbations-and-the-arg16-%C3%AE-2-receptor-polymorphism-a%C3%A2-meta-analysis-stratified-by-treatment
#9
Steve Turner, Ben Francis, Susanne Vijverberg, Maria Pino-Yanes, Anke H Maitland-van der Zee, Kaninika Basu, Lauren Bignell, Somnath Mukhopadhyay, Roger Tavendale, Colin Palmer, Daniel Hawcutt, Munir Pirmohamed, Esteban G Burchard, Brian Lipworth
BACKGROUND: The Gly-to-Arg substitution at the 16 position (rs1042713) in the β2-adrenoceptor gene (ADRB2) is associated with enhanced downregulation and uncoupling of β2-receptors. OBJECTIVES: We sought to undertake a meta-analysis to test the hypothesis that there is an interaction between the A allele of rs1042713 (Arg16 amino acid) and long-acting β-agonist (LABA) exposure for asthma exacerbations in children. METHODS: Children with diagnosed asthma were recruited in 5 populations (BREATHE, Genes-Environments and Admixture in Latino Americans II, PACMAN, the Paediatric Asthma Gene Environment Study, and the Pharmacogenetics of Adrenal Suppression with Inhaled Steroid Study)...
July 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/26725997/changing-patterns-of-asthma-medication-use-related-to-us-food-and-drug-administration-long-acting-%C3%AE-2-agonist-regulation-from-2005-2011
#10
Melissa G Butler, Esther H Zhou, Fang Zhang, Yu-te Wu, Ann Chen Wu, Mark S Levenson, Pingsheng Wu, Sally Seymour, Sengwee Toh, Aarthi Iyer, Solomon Iyasu, Meghan A Baker
BACKGROUND: Safety concerns associated with long-acting β2-agonists (LABAs) have led to many US Food and Drug Administration (FDA) regulatory activities for this class of drugs. Little is known about the effect of these regulatory activities on use of LABA-containing agents or other asthma medications. METHODS: We created rolling cohorts of pediatric and adult asthmatic patients in the Mini-Sentinel Distributed Database between January 2005 and June 2011. The proportions of asthmatic patients using LABA-containing products, inhaled corticosteroids (ICSs), leukotriene modifiers, short-acting β2-agonists, oral corticosteroids, other bronchodilators, and no medications were measured on a monthly basis, and the changes were evaluated by using interrupted time series with segmented regression analysis...
March 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/26606079/emerging-role-of-long-acting-anticholinergics-in-children-with-asthma
#11
REVIEW
Christian Vogelberg
PURPOSE OF REVIEW: Although the use of inhaled anticholinergics in obstructive airway disease has been established for several years, the clinical experience using these medications in treating patients with asthma is limited. Only few studies so far have included pediatric patients with asthma, but these studies demonstrate relevant therapeutic effects. This review will explore the pharmacological effects of inhaled anticholinergics, provide an overview about current adult and pediatric asthma studies using tiotropium, and describe future research needs...
January 2016: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/26594816/addition-of-long-acting-beta2-agonists-to-inhaled-corticosteroids-for-chronic-asthma-in-children
#12
REVIEW
Bhupendrasinh F Chauhan, Caroline Chartrand, Muireann Ni Chroinin, Stephen J Milan, Francine M Ducharme
BACKGROUND: Long-acting beta2-agonists (LABA) in combination with inhaled corticosteroids (ICS) are increasingly prescribed for children with asthma. OBJECTIVES: To assess the safety and efficacy of adding a LABA to an ICS in children and adolescents with asthma. To determine whether the benefit of LABA was influenced by baseline severity of airway obstruction, the dose of ICS to which it was added or with which it was compared, the type of LABA used, the number of devices used to deliver combination therapy and trial duration...
2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26171905/interventions-for-bronchiectasis-an-overview-of-cochrane-systematic-reviews
#13
REVIEW
Emma J Welsh, David J Evans, Stephen J Fowler, Sally Spencer
BACKGROUND: Bronchiectasis is a chronic respiratory disease characterised by abnormal dilatation of the bronchi, and presents typically with a chronic productive cough (or chronic wet cough in children) and recurrent infective exacerbations. It significantly impacts daily activities and quality of life, and can lead to recurrent hospitalisations, severe lung function impairment, respiratory failure and even death. OBJECTIVES: To provide an overview of the efficacy and safety of interventions for adults and children with bronchiectasis from Cochrane reviews...
July 14, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26097789/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-vilanterol-a-novel-inhaled-long-acting-%C3%AE-agonist-in-children-aged-5-11-years-with-persistent-asthma-a-randomized-trial
#14
Amanda Oliver, Sandi VanBuren, Ann Allen, Melanie Hamilton, Lee Tombs, Rodger Kempsford, Paul Qaqundah
This multi-center, randomized, double-blind, placebo-controlled, two-way crossover study was designed to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of single and once-daily repeat doses of vilanterol 25 µg in children aged 5-11 years. Twenty-eight children with persistent asthma received a single inhaled dose of vilanterol 25 µg or placebo via the ELLIPTA™ dry powder inhaler (DPI) on Day 1, followed 7 days later by once-daily treatment for 7 days. Nine (33%) subjects reported adverse events (AEs) with vilanterol 25 µg and 6 (23%) with placebo...
May 2014: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/26068328/initial-step-up-treatment-changes-in-asthmatic-children-already-prescribed-inhaled-corticosteroids-a-historical-cohort-study
#15
Steve W Turner, Kathryn Richardson, Annie Burden, Mike Thomas, Clare Murray, David Price
BACKGROUND: When standard doses of inhaled corticosteroids (ICS) fail to control symptoms in children aged >4 years, guidelines recommend the addition of a long-acting β2-agonist (LABA), with other treatment options being available if symptoms persist. AIMS: To determine the proportion of initial 'step-up' episodes where LABAs were prescribed and to describe characteristics of individuals not stepped up with LABA. METHODS: Between 1999 and 2011, initial step-up episodes from ICS monotherapy were identified in children aged 5-12 years with asthma and in receipt of ICS...
2015: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/26061910/effectiveness-of-drug-treatment-strategies-to-prevent-asthma-exacerbations-and-increase-symptom-free-days-in-asthmatic-children-a-network-meta-analysis
#16
Yile Zhao, Sheng Han, Jinxin Shang, Xizi Zhao, Run Pu, Luwen Shi
OBJECTIVE: To determine the effectiveness and safety of current maintenance therapies that include inhaled corticosteroids (ICS), long-acting β-agonists (LABA) and/or leukotriene receptor antagonists (LTRAs) in preventing exacerbations and improving symptoms in pediatric asthma. METHODS: A systematic review with network meta-analysis was conducted after a comprehensive search for relevant studies in the PubMed, Cochrane Library, Embase and Clinical Trials databases, up to July 2014...
October 2015: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/26032474/small-particle-inhaled-corticosteroid-as-first-line-or-step-up-controller-therapy-in-childhood-asthma
#17
COMPARATIVE STUDY
Willem M C van Aalderen, Jonathan Grigg, Theresa W Guilbert, Nicolas Roche, Elliot Israel, Richard J Martin, Gene Colice, Dirkje S Postma, Elizabeth V Hillyer, Anne Burden, Victoria Thomas, Julie von Ziegenweidt, David Price
BACKGROUND: Because randomized controlled trials of established pediatric asthma therapies are expensive and difficult to perform, observational studies may fill gaps in the evidence base. OBJECTIVES: To compare the effectiveness of representative small-particle inhaled corticosteroid (ICS) with that of standard size-particle ICS for children initiating or stepping up ICS therapy for asthma (analysis 1) and to compare the effectiveness of ICS dose step-up using small-particle ICS with adding long-acting β2-agonist (LABA) to the ICS (analysis 2)...
September 2015: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/25997166/stopping-long-acting-beta2-agonists-laba-for-children-with-asthma-well-controlled-on-laba-and-inhaled-corticosteroids
#18
REVIEW
Kayleigh M Kew, Sean Beggs, Shaleen Ahmad
BACKGROUND: Asthma is the most common chronic medical condition among children and is one of the most common causes of hospitalisation and medical visits. Poorly controlled asthma often leads to preventable exacerbations that require additional medications, hospital stays, or treatment in the emergency department.Long-acting beta2-agonists (LABA) are the preferred add-on treatment for children with asthma whose symptoms are not well controlled on inhaled corticosteroids (ICS). The US Food and Drug Administration has issued a 'black box' warning for LABA in asthma, and now recommends that they be used "for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved"...
2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/25275887/principal-findings-of-systematic-reviews-for-chronic-treatment-in-childhood-asthma
#19
REVIEW
Jose A Castro-Rodriguez, Gustavo J Rodrigo, Carlos E Rodriguez-Martinez
OBJECTIVE: To summarize the principal findings pertaining to most effective long-term pharmacologic treatment of childhood asthma. METHODS: Systematic reviews of randomized clinical trials (SRCTs) on pharmacologic chronic treatment in children (1-18 years) with persistent asthma were retrieved through MEDLINE, EMBASE, CINAHL, SCOPUS, and CDSR (up to January2014). RESULTS: One hundred eighty-three SRCTs were searched from databases. Among those, 39 SRCTs were included: two were related to step 1, 24 to step 2, nine to steps 3 and 4, and four to step 5 (according with NAEPP and GINA guidelines)...
May 2015: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/25213056/use-of-leukotriene-receptor-antagonists-are-associated-with-a-similar-risk-of-asthma-exacerbations-as-inhaled-corticosteroids
#20
Ann Chen Wu, Lingling Li, Vicki Fung, Elyse O Kharbanda, Emma K Larkin, William M Vollmer, Melissa G Butler, Irina Miroshnik, Donna Rusinak, Robert L Davis, Tina Hartert, Scott T Weiss, Tracy A Lieu
BACKGROUND: Based on results of clinical trials, inhaled corticosteroids (ICS) are the most-effective controller medications for preventing asthma-related exacerbations, yet few studies in real-life populations have evaluated the comparative effectiveness of ICS. OBJECTIVE: To determine the likelihood of asthma exacerbations among children with asthma after initiation of controller medications: ICS, leukotriene antagonists (LTRA), and ICS-long-acting β-agonist (LABA) combination therapy...
September 2014: Journal of Allergy and Clinical Immunology in Practice
keyword
keyword
115303
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"